CNMD - CONMED Corp Stock Price, Fair Value and News

69.40USD-2.25 (-3.14%)Market Closed

Market Summary

USD69.40-2.25

Market Closed

-3.14%

CNMD Alerts

1 major insider buys recently.

Big jump in Earnings (Y/Y)

CNMD Stock Price

View Fullscreen

CNMD RSI Chart

CNMD Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

25.96

Price/Sales (Trailing)

1.69

EV/EBITDA

19.45

Price/Free Cashflow

15.11

CNMD Price/Sales (Trailing)

CNMD Profitability

EBT Margin

8.23%

Return on Equity

9.64%

Return on Assets

3.57%

Free Cashflow Yield

6.62%

CNMD Fundamentals

CNMD Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

5.69%

Rev. Growth (Qtr)

-4.52%

CNMD Earnings

Earnings (TTM)

82.3M

Earnings Growth (Yr)

983.51%

Earnings Growth (Qtr)

-40.4%

Breaking Down CNMD Revenue

Last 7 days

1.6%

Last 30 days

-11.5%

Last 90 days

-17.8%

Trailing 12 Months

-42.9%

How does CNMD drawdown profile look like?

CNMD Financial Health

Current Ratio

2.18

Debt/Equity

1.16

Debt/Cashflow

0.16

CNMD Investor Care

Dividend Yield

1.15%

Dividend/Share (TTM)

0.8

Shares Dilution (1Y)

0.74%

Diluted EPS (TTM)

2.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.3B	0	0	0
2023	1.1B	1.1B	1.2B	1.2B
2022	1.0B	1.0B	1.1B	1.0B
2021	881.1M	978.5M	989.5M	1.0B
2020	950.7M	870.3M	874.5M	862.5M
2019	875.9M	901.4M	932.7M	955.1M
2018	811.9M	827.6M	839.7M	859.6M
2017	768.9M	772.6M	777.9M	796.4M
2016	722.4M	734.8M	750.4M	763.5M
2015	736.1M	728.9M	723.2M	719.2M
2014	757.6M	752.8M	748.5M	740.1M
2013	759.8M	763.1M	760.5M	762.7M
2012	735.9M	742.4M	751.5M	767.1M
2011	720.8M	723.0M	723.6M	725.1M
2010	699.5M	704.2M	709.0M	713.7M
2009	0	0	0	694.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of CONMED Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 06, 2024	aronson martha goldberg	bought	141,960	70.98	2,000	-
Apr 30, 2024	beyer pat	bought	204,900	68.3	3,000	chief operating officer
Mar 28, 2024	garner todd w	acquired	17,270	76.08	227	executive vice president & cfo
Mar 28, 2024	cohen heather l	acquired	17,270	76.08	227	evp & chief hr & legal officer
Mar 08, 2024	cohen heather l	sold (taxes)	-3,933,750	85.3216	-46,105	evp & chief hr & legal officer
Mar 08, 2024	cohen heather l	acquired	3,617,900	68.9124	52,500	evp & chief hr & legal officer
Mar 07, 2024	lalomia brent	acquired	-	-	75.00	vice president qa and ra
Mar 07, 2024	lalomia brent	sold (taxes)	-2,210	85.00	-26.00	vice president qa and ra
Dec 31, 2023	lalomia brent	acquired	1,997	109	18.243	vice president qa and ra
Dec 31, 2023	peters stanley w iii	acquired	12,173	109	111	president as and aet

Which funds bought or sold CNMD recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 07, 2024	QRG CAPITAL MANAGEMENT, INC.	reduced	-13.47	-237,384	408,770	-%
May 07, 2024	Headlands Technologies LLC	sold off	-100	-69,210	-	-%
May 07, 2024	Lisanti Capital Growth, LLC	sold off	-100	-4,442,820	-	-%
May 07, 2024	OPPENHEIMER ASSET MANAGEMENT INC.	reduced	-14.63	-1,339,780	2,226,300	0.03%
May 07, 2024	SUSQUEHANNA INTERNATIONAL GROUP, LLP	added	25.96	-168,832	1,971,650	-%
May 07, 2024	SEI INVESTMENTS CO	added	1.23	-17,370,600	49,505,000	0.07%
May 07, 2024	NEW YORK STATE COMMON RETIREMENT FUND	reduced	-11.64	-736,000	3,095,000	-%
May 07, 2024	Smithfield Trust Co	new	-	2,000	2,000	-%
May 07, 2024	Swiss National Bank	unchanged	-	-1,783,460	4,852,850	-%
May 07, 2024	Arizona State Retirement System	reduced	-1.66	-264,373	676,756	-%

Are Funds Buying or Selling CNMD?

Are funds buying CNMD calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CNMD

No. of Funds

Unveiling CONMED Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	vanguard group inc	11.12%	3,420,011	SC 13G/A
Feb 12, 2024	earnest partners llc	7.6%	2,345,697	SC 13G/A
Feb 09, 2024	capital research global investors	9.0%	2,757,108	SC 13G/A
Jan 22, 2024	blackrock inc.	16.4%	5,031,016	SC 13G/A
Feb 13, 2023	capital research global investors	7.2%	2,192,394	SC 13G
Feb 13, 2023	champlain investment partners, llc	4.19%	1,275,910	SC 13G/A
Feb 13, 2023	earnest partners llc	7.9%	2,402,352	SC 13G/A
Feb 09, 2023	vanguard group inc	11.23%	3,423,498	SC 13G/A
Jan 26, 2023	blackrock inc.	16.2%	4,922,968	SC 13G/A
Jan 20, 2023	blackrock inc.	16.2%	4,922,968	SC 13G/A

Recent SEC filings of CONMED Corp

View All Filings

Date Filed	Form Type	Document
May 08, 2024	4	Insider Trading
May 02, 2024	4	Insider Trading
Apr 26, 2024	4	Insider Trading
Apr 25, 2024	10-Q	Quarterly Report
Apr 24, 2024	8-K	Current Report
Apr 24, 2024	8-K	Current Report
Apr 08, 2024	DEF 14A	DEF 14A
Apr 08, 2024	DEFA14A	DEFA14A
Apr 08, 2024	ARS	ARS
Apr 03, 2024	4	Insider Trading

Peers (Alternatives to CONMED Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	182.6B	40.3B	-5.05%	-4.82%	32.45	4.53	-2.84%	-3.08%
BDX	67.4B	19.7B	-3.45%	-6.52%	50.6	3.42	4.82%	-17.56%
ALGN	20.6B	3.9B	-14.54%	-9.65%	44.54	5.26	5.72%	46.72%
BAX	18.2B	14.9B	-15.38%	-17.01%	6.88	1.22	2.98%	207.68%
MID-CAP
ATR	10.0B	3.5B	7.32%	25.05%	31.94	2.82	6.16%	35.06%
HSIC	9.3B	12.5B	0.39%	-2.78%	24.01	0.75	-0.61%	-18.83%
BIO	7.6B	2.6B	-17.82%	-26.90%	-23.72	2.94	-6.25%	-68.62%
XRAY	5.8B	3.9B	-13.74%	-32.04%	-61.76	1.47	0.23%	91.03%
AXNX	3.4B	387.1M	-0.59%	20.47%	-215.56	8.87	30.82%	65.57%
PDCO	2.3B	6.6B	-1.26%	-0.69%	11.98	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-6.92%	-14.34%	-1.85	0.4	7.94%	-1661.78%
ANIK	423.5M	169.3M	11.74%	12.93%	-5.51	2.5	7.49%	-244.90%
ANGO	236.7M	324.0M	-10.59%	-34.33%	-1.23	0.73	-3.19%	-337.41%
APYX	45.4M	52.3M	-10.27%	-60.90%	-2.43	0.87	17.61%	19.28%
AEMD	3.3M	3.7M	-25.00%	250.00%	-0.27	0.88	5.77%	8.23%

CONMED Corp News

Latest updates

CONMED Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-4.5%	312	327	305	318	295	251	275	277	242	274	249	255	233	253	238	158	214	265	234	238	218
Gross Profit	-5.6%	172	182	168	171	155	132	152	152	136	156	142	141	128	136	134	72.00	119	142	130	131	121
Operating Expenses	3.8%	137	132	138	143	143	133	127	127	114	119	116	116	108	111	104	93.00	106	114	109	113	110
S&GA Expenses	4.6%	123	118	125	130	130	121	115	116	103	107	105	104	98.00	99.00	94.00	84.00	96.00	102	98.00	101	99.00
R&D Expenses	-3.1%	14.00	14.00	12.00	14.00	13.00	12.00	13.00	11.00	11.00	11.00	11.00	11.00	10.00	12.00	10.00	9.00	10.00	12.00	11.00	12.00	11.00
EBITDA Margin	14.8%	0.13*	0.11*	0.07*	0.07*	-0.03*	-0.02*	0.01*	0.01*	0.12*	0.12*	0.11*	0.12*	-	-	-	-	-	-	-	-	-
Interest Expenses	0.9%	10.00	10.00	10.00	10.00	10.00	9.00	9.00	6.00	5.00	8.00	8.00	9.00	10.00	11.00	12.00	11.00	10.00	10.00	11.00	12.00	9.00
Income Taxes	-25.0%	6.00	8.00	4.00	4.00	1.00	-37.12	-30.44	75.00	2.00	5.00	2.00	3.00	-0.13	-10.64	11.00	-5.34	-2.44	2.00	2.00	1.00	-2.98
Earnings Before Taxes	-37.5%	25.00	41.00	20.00	17.00	2.00	-10.54	16.00	-93.48	17.00	30.00	17.00	16.00	10.00	13.00	17.00	-32.74	3.00	17.00	9.00	6.00	-1.96
EBT Margin	26.7%	0.08*	0.06*	0.03*	0.02*	-0.08*	-0.07*	-0.03*	-0.03*	0.08*	0.07*	0.06*	0.06*	-	-	-	-	-	-	-	-	-
Net Income	-40.4%	20.00	33.00	16.00	14.00	2.00	27.00	46.00	-168	15.00	24.00	15.00	13.00	10.00	24.00	7.00	-27.40	6.00	15.00	7.00	6.00	1.00
Net Income Margin	26.1%	0.07*	0.05*	0.05*	0.08*	-0.09*	-0.08*	-0.08*	-0.11*	0.07*	0.06*	0.06*	0.06*	-	-	-	-	-	-	-	-	-
Free Cashflow	-47.4%	27.00	52.00	41.00	22.00	-8.10	-17.27	19.00	13.00	-3.36	31.00	16.00	31.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.4%	2,309	2,300	2,326	2,323	2,320	2,298	2,292	2,072	1,786	1,766	1,754	1,762	1,747	1,752	1,743	1,724	1,751	1,775	1,758	1,759	1,761
Current Assets	3.3%	636	616	626	616	610	581	574	577	488	460	443	443	424	417	404	379	393	397	399	397	391
Cash Equivalents	39.3%	34.00	24.00	31.00	28.00	26.00	29.00	33.00	53.00	25.00	21.00	32.00	46.00	37.00	27.00	36.00	35.00	24.00	26.00	30.00	23.00	23.00
Inventory	1.2%	322	318	326	327	335	332	305	290	254	232	229	211	206	195	183	176	175	165	174	173	171
Net PPE	-2.3%	118	121	120	117	115	116	114	112	109	109	109	108	109	111	112	113	114	119	117	117	117
Goodwill	-0.1%	806	807	815	816	815	815	814	757	618	618	618	618	618	618	617	617	616	618	616	616	615
Liabilities	-0.8%	1,455	1,466	1,529	1,543	1,568	1,552	1,576	1,399	996	981	998	1,017	1,021	1,043	1,060	1,049	1,049	1,065	1,057	1,062	1,068
Current Liabilities	-6.2%	291	311	376	353	321	297	209	201	188	197	183	198	182	190	179	151	160	188	161	156	151
Long Term Debt	1.7%	990	973	942	971	995	985	1,036	982	704	672	703	708	725	735	760	790	773	755	781	796	804
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	13.00	14.00	14.00
LT Debt, Non Current	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	781	796	804
Shareholder's Equity	2.5%	855	834	796	780	752	746	716	673	790	785	756	744	726	709	683	675	702	710	701	697	693
Retained Earnings	3.0%	466	453	426	416	408	413	392	352	526	497	478	469	461	457	439	438	471	471	462	460	460
Additional Paid-In Capital	2.6%	458	447	440	433	420	413	407	401	366	397	395	394	389	383	381	377	375	379	379	377	375
Shares Outstanding	-	31.00	-	31.00	31.00	31.00	-	30.00	30.00	29.00	-	29.00	29.00	29.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	3,100	-	-	-	2,200	-	-	-	2,900	-	-	-	1,500	-	-	-	2,421	-

Cashflow (Last 12 Months)

(In Thousands)

Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-48.4%	29,121	56,395	46,127	26,673	-3,847	-11,598	25,893	18,742	328	33,785	21,362	34,279	22,344	20,145	35,126	5,539	3,721	40,876	36,600	21,577	-3,920
Share Based Compensation	5.4%	6,240	5,923	6,186	6,422	5,726	5,728	5,754	5,755	4,463	4,297	4,327	4,289	3,387	2,981	3,532	3,555	3,032	2,960	3,008	3,108	2,703
Cashflow From Investing	58.1%	-2,035	-4,855	-5,394	-5,529	-4,254	-6,318	-91,258	-148,266	-3,687	-3,188	-5,575	-2,994	-3,109	-3,149	-60.00	-3,752	-6,677	-8,859	-4,869	-4,984	-368,950
Cashflow From Financing	71.0%	-17,014	-58,766	-37,229	-19,787	5,350	11,515	46,875	159,121	7,489	-40,789	-29,792	-22,095	-8,872	-27,164	-35,665	8,031	2,739	-36,974	-23,424	-17,675	378,954
Dividend Payments	0.1%	6,153	6,149	6,145	6,110	6,098	6,095	6,092	5,899	5,874	5,838	5,830	5,813	5,775	5,719	5,712	5,704	5,683	5,673	5,658	5,643	5,626

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

CNMD Income Statement

2024-03-31

Consolidated Condensed Statements of Comprehensive Income (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Statement of Comprehensive Income [Abstract]
Net sales	$ 312,273	$ 295,468
Cost of sales	140,308	140,147
Gross profit	171,965	155,321
Selling and administrative expense	123,358	130,083
Research and development expense	13,594	12,539
Operating expenses	136,952	142,622
Income from operations	35,013	12,699
Interest expense	9,594	10,255
Income before income taxes	25,419	2,444
Provision for income taxes	5,710	625
Net income	19,709	1,819
Comprehensive income	$ 20,078	$ 4,695
Per share data:
Basic (in dollars per share)	$ 0.64	$ 0.06
Diluted (in dollars per share)	$ 0.63	$ 0.06
Weighted average common shares:
Basic (in shares)	30,780	30,511
Diluted (in shares)	31,272	31,204

CNMD Balance Sheet

2024-03-31

Consolidated Condensed Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 33,855	$ 24,296
Accounts receivable, net	241,461	242,279
Inventories	322,298	318,324
Prepaid expenses and other current assets	38,110	30,750
Total current assets	635,724	615,649
Property, plant and equipment, net	117,951	120,722
Goodwill	806,276	806,844
Other intangible assets, net	641,310	649,484
Other assets	107,994	107,322
Total assets	2,309,255	2,300,021
Current liabilities:
Current portion of long-term debt	692	708
Accounts payable	101,635	88,224
Accrued compensation and benefits	49,931	70,069
Other current liabilities	139,146	151,728
Total current liabilities	291,404	310,729
Long-term debt	990,110	973,140
Deferred income taxes	64,002	60,902
Other long-term liabilities	109,075	121,028
Total liabilities	1,454,591	1,465,799
Commitments and contingencies
Shareholders' equity:
Preferred stock, par value $.01 per share; authorized 500,000 shares; none outstanding	0	0
Common stock, par value $0.01 per share; 100,000,000 shares authorized; 31,299,194 shares issued in 2024 and 2023, respectively	313	313
Paid-in capital	458,024	446,535
Retained earnings	466,082	452,531
Accumulated other comprehensive loss	(49,801)	(50,170)
Less: 508,028 and 534,000 shares of common stock in treasury, at cost, in 2024 and 2023, respectively	(19,954)	(14,987)
Total shareholders’ equity	854,664	834,222
Total liabilities and shareholders’ equity	$ 2,309,255	$ 2,300,021

About CONMED Corp

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. It offers orthopedic surgery products, including TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide unique clinical solutions to orthopedic surgeons for the repair of soft tissue injuries, as well as supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. The company markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. It also offers general surgery products, such as clinical insufflation, smoke evacuation, electrosurgical, and endomechanical products; and endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. The company markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.

CEO	Mr. Curt R. Hartman
WEBSITE	conmed.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	4100

CONMED Corp Frequently Asked Questions

What is the ticker symbol for CONMED Corp? What does CNMD stand for in stocks?

CNMD is the stock ticker symbol of CONMED Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of CONMED Corp (CNMD)?

As of Wed May 08 2024, market cap of CONMED Corp is 2.14 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNMD stock?

You can check CNMD's fair value in chart for subscribers.

What is the fair value of CNMD stock?

You can check CNMD's fair value in chart for subscribers. The fair value of CONMED Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of CONMED Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNMD so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is CONMED Corp a good stock to buy?

The fair value guage provides a quick view whether CNMD is over valued or under valued. Whether CONMED Corp is cheap or expensive depends on the assumptions which impact CONMED Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNMD.

What is CONMED Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 08 2024, CNMD's PE ratio (Price to Earnings) is 25.96 and Price to Sales (PS) ratio is 1.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CNMD PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on CONMED Corp's stock?

In the past 10 years, CONMED Corp has provided 0.048 (multiply by 100 for percentage) rate of return.